Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer

NCT04257864 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2020-02-10

No results posted yet for this study

Summary

To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating patients with the diagnosis of advanced Non-Small-Lung-Cancer.

Conditions

  • Non Small Cell Lung Cancer

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-05-31
Completion
2014-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04257864 on ClinicalTrials.gov